MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma

Authors: Laurie Sehn,1 Clémentine Sarkozy,2 Yuqin Song,3 Antonio Salar,4 Judith Trotman,5 Pier Luigi Zinzani,6 Jun Zhang,7 Wanhua Zhang,7 Pierre Fustier,7 Richard Delarue,7 and Loretta Nastoupil8

Affiliations: 1University of British Columbia, Vancouver, BC, Canada; 2Institut Curie, Saint Cloud, Paris, France; 3Peking University Cancer Hospital and Institute, Beijing, China; 4Hospital del Mar, Barcelona, Spain; 5Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia; 6Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy; 7BeiGene (Shanghai) Co., Ltd. Shanghai, China and BeiGene USA, Inc., San Mateo, CA, USA; and 8MD Anderson Cancer Center, Houston, TX, USA

Introduction: Inhibition of Bruton tyrosine kinase (BTK) has emerged as a strategy for treatment of patients (pts) with B-cell malignancies including indolent non-Hodgkin lymphomas. Zanubrutinib is a second-generation, potent, and specific BTK inhibitor and has shown to be more effective and better tolerated than first-generation BTK inhibitors in several diseases including chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenström macroglobulinemia. Zanubrutinib is approved in >15 countries, including the United States and European Union, for pts with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who received ≥1 anti-CD20–based regimen, based on the single-arm MAGNOLIA trial (Opat et al. Clin Cancer Res 2021). In R/R follicular lymphoma (FL), ROSEWOOD, a phase 2 randomized study of zanubrutinib plus obinutuzumab vs obinutuzumab, met its primary endpoint of increased overall response rate (ORR) at primary analysis (Zinzani et al. J Clin Oncol 2022). In this trial, zanubrutinib plus obinutuzumab in pts with R/R FL demonstrated deep and durable responses with a favorable safety profile.

Methods: MAHOGANY (BGB-3111-308, NCT05100862) is a phase 3 randomized, open-label trial that compares efficacy and safety of a combination of zanubrutinib plus anti-CD20 monoclonal antibody vs lenalidomide plus rituximab in 2 independent cohorts, for pts with either R/R FL or MZL. Key eligibility criteria include histologically confirmed FL (grades 1-3A) or MZL, previously treated with ≥1 anti-CD20-based regimen, relapsed after or refractory to the most recent systemic therapy, in need of treatment, no prior BTK inhibitor exposure, and no prior resistance to a lenalidomide-based regimen. In the FL cohort, pts will be randomized 1:1 to zanubrutinib plus obinutuzumab (N=300) and lenalidomide plus rituximab (N=300). Randomization is stratified by age (≥60 vs <60 years), number of prior lines of therapy (1-2 vs >2), and rituximab-refractory status (yes vs no). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) according to Lugano 2014 criteria. Key secondary endpoints are ORR by IRC assessment and overall survival. In the MZL cohort, pts will be randomized 1:1 to zanubrutinib plus rituximab (N=75) and lenalidomide plus rituximab (N=75). Randomization is stratified by age (≥60 vs <60 years) and number of prior lines of therapy (1-2 vs >2). The primary endpoint is PFS assessed by IRC according to Lugano 2014 criteria. The key
secondary endpoint is ORR by IRC assessment. Zanubrutinib is given at 160 mg twice daily or 320 mg once daily according to investigator, until progression or unacceptable toxicity. Obinutuzumab or rituximab are given for up to 8 infusions. Lenalidomide is given according to approved label for up to 12 cycles. Recruitment is ongoing.